NasdaqCM - Nasdaq Real Time Price USD

Galmed Pharmaceuticals Ltd. (GLMD)

0.3835

-0.0046

(-1.19%)

As of 1:39 PM EDT. Market Open.

Wall Street Favorites: 3 Penny Stocks With Strong Buy Ratings for April 2024

Now could be a great time for investors to consider stacking up on penny stocks. These companies often have significant growth potential. But they trade at low prices, typically under $5 per share. Penny stocks tend to be highly volatile, with the potential for rapid gains or losses. This requires careful research and risk management. Fortunately, some of the better-known penny stocks are covered by Wall Street analysts who give strong buy ratings. This is a positive indicator, as analysts close

InvestorPlace 16 days ago

GLMD
-1.19%
TCON
Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2023

Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and fibrotic diseases, today announced that it has filed its Annual Report on Form 20-F for the fiscal year ended December 31, 2023, with the U.S. Securities and Exchange Commission (the "SEC").

PR Newswire 21 days ago

GLMD
-1.19%
Galmed Announces Grant of New Patent for the Combination of Aramchol with Resmetirom (MGL-3196, REZDIFFRA) for the Treatment of NASH and Liver Fibrosis

Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and fibrotic diseases announced today the grant of a European patent related to the use of a combination of Aramchol and Resmetirom (MGL-3196, REZDIFFRA) for the treatment of NASH/MASH and liver fibrosis. The patent was granted in France, Germany, Italy, the Netherlands and the United Kingdom and the approval of the patent in the United States and other countrie

PR Newswire last month

GLMD
-1.19%
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

It’s time to start Tuesday trading with a breakdown of the biggest pre-market stock movers worth watching this morning! Moving stocks this morning are collaboration agreements, merger plans, earnings, public share offerings and more. Let’s get into that news down below!InvestorPlace - Stock Market News, Stock Advice & Trading Tips Biggest Pre-Market Stock Movers: 10 Top Gainers Tracon Pharmaceuticals (NASDAQ:TCON) stock is rocketing more than 54% with heavy trading after announcing a product dev

InvestorPlace 5 months ago

GLMD
-1.19%
TCON

SYM
Galmed Announces a delay in the initiation of its Primary Sclerosing Cholangitis (PSC) Phase 2a Study

Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and fibrotic diseases, announced today a delay of at least 6 months in the initiation of its Primary Sclerosing Cholangitis (PSC) Ph 2a Study.

PR Newswire 5 months ago

GLMD
-1.19%
Galmed Announces Allowance of New Patent for Aramchol for the Treatment of Pulmonary and Dermal Fibrosis

Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and fibrotic diseases announced today the allowance of a Japanese patent related to treatment of pulmonary and dermal fibrosis. A similar patent was already granted in Mexico. The approval of the patent in the US and the rest of the world is pending. With this latest patent, Galmed is strengthening and extending the patent protection of its lead compound, Aramch

PR Newswire 6 months ago

GLMD
-1.19%
Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification

TEL AVIV, Israel, Sept. 22, 2023 /PRNewswire/ —Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and fibrotic diseases, today announced that the Company received a letter from the Nasdaq Listing Qualifications (the "Letter"), indicating that the Company is not in compliance with the minimum bid price requirement for continued listing set forth in Listing Rule 5550(a)(2), which requires listed securities to main

PR Newswire 6 months ago

GLMD
-1.19%
Galmed Pharmaceuticals Announces Pricing of $7 Million Public Offering

Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and fibrotic diseases, announced today that it has entered into securities purchase agreements with two institutional investors to purchase 5,600,000 of its ordinary shares (or pre-funded warrants in lieu thereof) and warrants to purchase 5,600,000 ordinary shares at a combined purchase price of $1.25 per ordinary share and accompanying warrant (the "Offering").

PR Newswire 9 months ago

GLMD
-1.19%
Galmed to employ OnKai's disruptive Artificial Intelligence (AI) in its Planned Phase 2a Clinical Trial in PSC

Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and fibrotic diseases, is delighted to announce the first step in its strategic partnership with OnKai, where OnKai will apply its artificial intelligence (AI), models for enrollment and execution of clinical trials in underserved communities, starting with Galmed's innovative Primary Sclerosing Cholangitis (PSC) clinical development program.

PR Newswire 9 months ago

GLMD
-1.19%
Galmed Pharmaceuticals Reports First Quarter 2023 Financial Results and Recent Developments

Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver and fibro-inflammatory diseases reports financial results for the three months ended March 31, 2023 and recent developments

PR Newswire 10 months ago

GLMD
-1.19%
Galmed Announces Initiation of a Clinical Development Program to Evaluate Aramchol meglumine for the Treatment of Primary Sclerosing Cholangitis (PSC)

Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and fibrotic diseases, today announced the initiation of a new clinical program to evaluate its lead compound, Aramchol meglumine for the Treatment of Primary Sclerosing Cholangitis (PSC).

PR Newswire 11 months ago

GLMD
-1.19%
Galmed Pharmaceuticals forms a Strategic Partnership with OnKai

Galmed Pharmaceuticals Ltd. (GLMD) reported today the execution of a definitive agreement for a $3M equity investment in OnKai Inc., leading an investment round of $6M. The agreement provides Galmed with a minority, but a strategic stake in Onkai. Concurrently, a strategic partnership agreement is being signed to advance both companies by leveraging their complementary knowledge and experience in their respective fields.

PR Newswire 11 months ago

GLMD
-1.19%

Performance Overview

Return	GLMD	S&P 500
YTD	-15.71%	+7.11%
1-Year	+23.71%	+25.48%
3-Year	-88.24%	+22.22%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Galmed Pharmaceuticals Ltd. (GLMD)

Wall Street Favorites: 3 Penny Stocks With Strong Buy Ratings for April 2024

Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2023

Galmed Announces Grant of New Patent for the Combination of Aramchol with Resmetirom (MGL-3196, REZDIFFRA) for the Treatment of NASH and Liver Fibrosis

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

Galmed Announces a delay in the initiation of its Primary Sclerosing Cholangitis (PSC) Phase 2a Study

Galmed Announces Allowance of New Patent for Aramchol for the Treatment of Pulmonary and Dermal Fibrosis

Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification

Galmed Pharmaceuticals Announces Pricing of $7 Million Public Offering

Galmed to employ OnKai's disruptive Artificial Intelligence (AI) in its Planned Phase 2a Clinical Trial in PSC

Galmed Pharmaceuticals Reports First Quarter 2023 Financial Results and Recent Developments

Galmed Announces Initiation of a Clinical Development Program to Evaluate Aramchol meglumine for the Treatment of Primary Sclerosing Cholangitis (PSC)

Galmed Pharmaceuticals forms a Strategic Partnership with OnKai

Performance Overview